Cash, cash equivalents and marketable securities were $861.7 million as of December 31, 2024, compared to $1.0 billion as of December 31, 2023. The Company’s cash position as of December 31, 2024, is expected to fund operations into the first half of 2027.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- NTLA Upcoming Earnings Report: What to Expect?
- NTLA LAWSUIT ALERT: Levi & Korsinsky LLP Notifies Intellia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
- Twilio, Qorvo upgraded: Wall Street’s top analyst calls
- Intellia Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley
- Intellia Therapeutics announces first patient dosed in Phase 3 NTLA-2002